Jivi (Antihemophilic Factor Drug Interactions: 40 Major
Jivi (Antihemophilic Factor (Recombinant) Pegylated-Aucl) Drug Interactions
Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Jivi. Always confirm against the full prescribing information.
55 interactions
Certolizumab pegol
The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Certolizumab pegol.
Level 2 evidence
Elapegademase
The therapeutic efficacy of Elapegademase can be decreased when used in combination with Damoctocog alfa pegol.
Level 2 evidence
Fitusiran
The risk or severity of hypercoagulability can be increased when Damoctocog alfa pegol is combined with Fitusiran.
Level 1 evidence
Methoxy polyethylene glycol-epoetin beta
The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta.
Level 2 evidence
Pegaspargase
The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Pegaspargase.
Level 2 evidence
Pegfilgrastim
The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Pegfilgrastim.
Level 2 evidence
Peginterferon alfa-2a
The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Peginterferon alfa-2a.
Level 2 evidence
Peginterferon alfa-2b
The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Peginterferon alfa-2b.
Level 2 evidence
Peginterferon beta-1a
The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Peginterferon beta-1a.
Level 2 evidence
Pegloticase
The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Pegloticase.
Level 2 evidence
Pegvaliase
The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Pegvaliase.
Level 2 evidence
Pegvisomant
The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Pegvisomant.
Level 2 evidence
Enter your NPI to unlock 40 major interactions for Jivi
Jivi (Antihemophilic Factor (Recombinant) Pegylated-Aucl) has 55 documented drug interactions. Always review the full list with a pharmacist before co-prescribing.
Jivi (Antihemophilic Factor (Recombinant) Pegylated-Aucl) has 40 major, 0 moderate, and 15 minor documented interactions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Jivi. Always confirm against the full prescribing information.